|48.22||+0.2800||+0.58%||Vol 9.08M||1Y Perf 11.83%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||0.35 0.73%|
|Target Price||49.61||Analyst Rating||Strong Buy 1.47|
|Potential %||2.88||Finscreener Ranking||★ 40.16|
|Insiders Trans % 3/6/12 mo.||-100/-100/-96||Value Ranking||★ 41.65|
|Insiders Value % 3/6/12 mo.||-100/-100/-96||Growth Ranking||★★ 43.98|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-96||Income Ranking||— -|
|Price Range Ratio 52W %||92.98||Earnings Rating||Sell|
|Market Cap||69.31B||Earnings Date||26th Apr 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Apr 2023|
|Estimated EPS Next Report||0.44|
|EPS Growth Next 5 Years %||10.30|
|Avg. Weekly Volume||8.35M|
|Avg. Monthly Volume||7.55M|
|Avg. Quarterly Volume||7.00M|
Boston Scientific Corporation (NYSE: BSX) stock closed at 48.22 per share at the end of the most recent trading day (a 0.58% change compared to the prior day closing price) with a volume of 9.08M shares and market capitalization of 69.31B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 38000 people. Boston Scientific Corporation CEO is Michael F. Mahoney.
The one-year performance of Boston Scientific Corporation stock is 11.83%, while year-to-date (YTD) performance is 4.21%. BSX stock has a five-year performance of 83.35%. Its 52-week range is between 34.98 and 49.22, which gives BSX stock a 52-week price range ratio of 92.98%
Boston Scientific Corporation currently has a PE ratio of 110.30, a price-to-book (PB) ratio of 3.76, a price-to-sale (PS) ratio of 6.92, a price to cashflow ratio of 55.70, a PEG ratio of 2.32, a ROA of 2.02%, a ROC of 3.66% and a ROE of 3.77%. The company’s profit margin is 5.91%, its EBITDA margin is 19.80%, and its revenue ttm is $9.44 Billion , which makes it $6.59 revenue per share.
Of the last four earnings reports from Boston Scientific Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.44 for the next earnings report. Boston Scientific Corporation’s next earnings report date is 26th Apr 2023.
The consensus rating of Wall Street analysts for Boston Scientific Corporation is Strong Buy (1.47), with a target price of $49.61, which is +2.88% compared to the current price. The earnings rating for Boston Scientific Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Boston Scientific Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Boston Scientific Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 9.31, ATR14 : 0.84, CCI20 : 49.87, Chaikin Money Flow : 0.16, MACD : 0.38, Money Flow Index : 59.80, ROC : 2.84, RSI : 55.79, STOCH (14,3) : 66.89, STOCH RSI : 0.25, UO : 58.61, Williams %R : -33.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Boston Scientific Corporation in the last 12-months were: Arthur C. Butcher (Option Excercise at a value of $425 713), Arthur C. Butcher (Sold 47 538 shares of value $2 240 246 ), Daniel J. Brennan (Option Excercise at a value of $771 751), Daniel J. Brennan (Sold 113 182 shares of value $5 283 178 ), Eric Francis Yves Thepaut (Option Excercise at a value of $0), Eric Francis Yves Thepaut (Sold 35 628 shares of value $1 486 283 ), Ian T. Meredith (Sold 6 588 shares of value $287 764 ), Jeffrey B. Mirviss (Option Excercise at a value of $387 155), Jeffrey B. Mirviss (Sold 88 620 shares of value $4 095 675 ), Jodi Euerle Eddy (Sold 2 779 shares of value $125 055 ), John Bradley Sorenson (Option Excercise at a value of $0), Jonathan Monson (Option Excercise at a value of $0), Jonathan R. Monson (Option Excercise at a value of $64 450), Jonathan R. Monson (Sold 5 000 shares of value $233 315 ), Joseph M. Fitzgerald (Option Excercise at a value of $585 761), Joseph M. Fitzgerald (Sold 79 264 shares of value $3 787 234 ), Meghan Scanlon (Option Excercise at a value of $0), Michael F. Mahoney (Option Excercise at a value of $4 704 070), Michael F. Mahoney (Sold 503 310 shares of value $20 479 545 ), Nelda J. Connors (Sold 34 284 shares of value $1 478 183 ), Scott Olson (Sold 700 shares of value $31 185 ), Vance R. Brown (Option Excercise at a value of $0), Wendy Carruthers (Option Excercise at a value of $94 954), Wendy Carruthers (Sold 139 171 shares of value $5 789 872 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
CEO: Michael F. Mahoney
Telephone: +1 508 683-4000
Address: 300 Boston Scientific Way, Marlborough 01752-1234, MA, US
Number of employees: 38 000
Sat, 04 Mar 2023 01:55 GMT Boston Scientific (BSX) Receives a Buy from RBC Capital- TipRanks. All rights reserved.
Fri, 03 Feb 2023 03:20 GMT Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Humana (HUM)- TipRanks. All rights reserved.
Thu, 02 Feb 2023 13:20 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN), Boston Scientific (BSX) and Evelo Biosciences (EVLO)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.